Physician profile
Steven C Ayers
NPI 1225425754
$720.39
in general payments reported to CMS, 2019-2025
14 companies · $18.65 in 2025
The $18.65 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $66.78 · 2023: $165 · 2024: $325 · 2025: $18.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $107.26 | 2021-2024 | Rexulti |
| Corium, LLC | $97.40 | 2023-2024 | Azstarys |
| Abbvie INC. | $89.13 | 2022-2024 | Vraylar |
| Tris Pharma INC | $82.09 | 2023-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $69.99 | 2021-2025 | Entyvio |
| Janssen Pharmaceuticals, INC | $57.15 | 2021-2023 | Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $55.31 | 2021 | |
| Alkermes, INC. | $39.37 | 2022-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $29.50 | 2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.10 | 2023 | |
| Axsome Therapeutics, INC. | $21.13 | 2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $19.12 | 2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $17.92 | 2024 | |
| Vanda Pharmaceuticals INC. | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.